Janette Sutton - Concepedia

Author

Janette Sutton

Pfizer (United States)ORCID

Also Known As

J E Sutton, Janette E Sutton, Janette E. Sutton, Janette Sutton

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Allogene Therapeutics (United States)Cellectis (United States)

About

Janette Sutton is an author at Pfizer (United States) specializing in medicine, antibody engineering, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	302
2	Engineering	1	1	59
3	Social Sciences	1	1	35
4	Allergy	1	1	145
5	Biomedical Engineering	1	1	63

Janette Sutton

Publications

986

Citations

H-Index

Page 1

	Year	Citations
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 Javier Chaparro‐Riggers, Liang Hong, Rachel M. DeVay, Journal of Biological Chemistry	2012	164
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma Cesar Sommer, Bijan Boldajipour, Tracy C. Kuo, Molecular Therapy	2019	156
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair Pavel Strop, Wei-Hsien Ho, Leila M. Boustany, Journal of Molecular Biology Immunocytochemical TechniqueAllergyHuman Leukocyte AntigenAutoimmune DiseaseIgg2 Antibodies	2012	145
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates Liang Hong, Javier Chaparro‐Riggers, Pavel Strop, Journal of Pharmacology and Experimental Therapeutics	2011	105
CGRP function‐blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat James R. Zeller, Kris Poulsen, Janette Sutton, British Journal of Pharmacology	2008	88
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery Cesar Sommer, Hsin‐Yuan Cheng, Duy Nguyen, Molecular Therapy	2020	82
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy Magdalena Dorywalska, Pavel Strop, Jody A. Melton-Witt, PLoS ONE Rodent PlasmaImmunocytochemical TechniqueMedicineSite-dependent DegradationConjugation Sites	2015	63
Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates Rachel M. DeVay, Kathy Delaria, Guoyun Zhu, Bioconjugate Chemistry Immunocytochemical TechniqueEngineeringLysosomal Storage DiseaseImmunologyImmunotherapeutics	2017	59
Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer Yi Zhang, Silvia K. Tacheva-Grigorova, Janette Sutton, Clinical Cancer Research	2023	46
Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: Lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice Jordan Mechanic, Janette Sutton, Amy E. Berson, European Neuropsychopharmacology HypertensionBehavioral NeuroscienceMedicineSympathetic Nervous SystemBehavioral Pharmacology	2009	35

Page 1